Home › Companies › MADRIGAL PHARMACEUTICALS INC. › 2023-2024

MADRIGAL PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Ballot items
285Asset managers
1,840Fund votes
June 25, 2024Meeting date

Results at a glance

Meeting of June 25, 2024: 6 items on MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024: 3 elected · 3 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MADRIGAL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MADRIGAL PHARMACEUTICALS INC.

These tallies are MADRIGAL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MADRIGAL PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 25, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Bill Sibold	16,222,905	--	--	154,896	2,188,174	99.0%	Elected	—
Elect Director: Rebecca Taub, M.D.	16,045,750	--	--	332,051	2,188,174	98%	Elected	—
Elect Director: Fred B. Craves, Ph.D.	14,311,451	--	--	2,066,303	2,188,221	87%	Elected	—
2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024	18,444,828	110,517	10,630	--	--	99.4%	Approved	—
3. The compensation of the Company's named executive officers as described in the Proxy Statement	15,585,020	781,212	11,522	--	2,188,221	95%	Approved	—
4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Proxy Statement	15,941,045	428,537	8,219	--	2,188,174	97%	Approved	—

Source: MADRIGAL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 27, 2024 — read the filing on EDGAR.

How asset managers voted at the MADRIGAL PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 285 asset managers that disclosed a MADRIGAL PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Bill Sibold

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%

FOR: 16,222,905WITHHELD: 154,896

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Re-election of Class II directors: Bill Sibold

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bill Sibold”): 16,222,905 for, 154,896 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 5,715,165 for, 67,243 withheld.

FOR

FOR: 5,715,165WITHHOLD: 67,243

Largest asset managers voting on “Re-election of Class II directors: Bill Sibold” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
JANUS INVESTMENT FUND	1,772,021	0	For
Vanguard	1,675,430	0	For
T. Rowe Price	587,672	0	For
BlackRock	390,103	0	For
Artisan	251,283	0	For
Charles Schwab	123,656	0	For
American Century	91,230	0	For
Fidelity	76,653	0	For
OLD WESTBURY FUNDS INC	54,469	0	For
Lord Abbett	54,435	0	For
TIAA	49,103	0	For
JANUS ASPEN SERIES	42,402	0	For
FINANCIAL INVESTORS TRUST	0	38,632	Withhold
Brighthouse	36,133	884	For
Pacific Life	36,870	0	For
Invesco	35,339	0	For
State Street	31,129	0	For
Equitable	30,800	0	For
Delaware/Macquarie	30,140	0	For
Principal	1,732	27,194	Mixed
Jackson National	27,935	0	For
AIG/SunAmerica	26,143	0	For
Direxion Shares ETF Trust	23,016	0	For
Waddell & Reed	22,182	0	For
ALGER FUNDS II	20,392	0	For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

2. Elect Director: Fred B. Craves, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 14,311,451WITHHELD: 2,066,303

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Re-election of Class II directors: Fred B. Craves, Ph.D.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fred B. Craves, Ph.D.”): 14,311,451 for, 2,066,303 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 4,729,985 for, 1,052,423 withheld.

FORWITHHOLD

FOR: 4,729,985WITHHOLD: 1,052,423

Largest asset managers voting on “Re-election of Class II directors: Fred B. Craves, Ph.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
JANUS INVESTMENT FUND	1,772,021	0	For
Vanguard	1,596,441	78,989	For
T. Rowe Price	587,672	0	For
BlackRock	0	390,103	Withhold
Artisan	251,283	0	For
Charles Schwab	0	123,656	Withhold
American Century	91,230	0	For
Fidelity	70,387	6,266	Mixed
OLD WESTBURY FUNDS INC	54,469	0	For
Lord Abbett	54,435	0	For
TIAA	0	49,103	Withhold
JANUS ASPEN SERIES	42,402	0	For
FINANCIAL INVESTORS TRUST	0	38,632	Withhold
Brighthouse	981	36,036	Withhold
Pacific Life	31,865	5,005	Mixed
Invesco	0	35,339	Withhold
State Street	67	31,062	Withhold
Equitable	3,090	27,710	Mixed
Delaware/Macquarie	0	30,140	Withhold
Principal	1,732	27,194	Mixed
Jackson National	0	27,935	Withhold
AIG/SunAmerica	26,143	0	For
Direxion Shares ETF Trust	23,016	0	For
Waddell & Reed	0	22,182	Withhold
ALGER FUNDS II	0	20,392	Withhold

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

3. Elect Director: Rebecca Taub, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 16,045,750WITHHELD: 332,051

Details: description as filed, official tally, votes by 79 asset managers

Description as filed by funds: Re-election of Class II directors: Rebecca Taub, M.D.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rebecca Taub, M.D.”): 16,045,750 for, 332,051 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 79 asset managers below reported 5,671,061 for, 111,347 withheld.

FOR

FOR: 5,671,061WITHHOLD: 111,347

Largest asset managers voting on “Re-election of Class II directors: Rebecca Taub, M.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
JANUS INVESTMENT FUND	1,772,021	0	For
Vanguard	1,675,430	0	For
T. Rowe Price	587,672	0	For
BlackRock	390,103	0	For
Artisan	251,283	0	For
Charles Schwab	123,656	0	For
American Century	91,230	0	For
Fidelity	76,653	0	For
OLD WESTBURY FUNDS INC	54,469	0	For
Lord Abbett	54,435	0	For
TIAA	49,103	0	For
JANUS ASPEN SERIES	42,402	0	For
FINANCIAL INVESTORS TRUST	0	38,632	Withhold
Brighthouse	36,133	884	For
Pacific Life	36,870	0	For
Invesco	35,339	0	For
State Street	72	31,057	Withhold
Equitable	30,800	0	For
Delaware/Macquarie	30,140	0	For
Principal	1,732	27,194	Mixed
Jackson National	27,935	0	For
AIG/SunAmerica	26,143	0	For
Direxion Shares ETF Trust	23,016	0	For
Waddell & Reed	22,182	0	For
ALGER FUNDS II	20,392	0	For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

4. 4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of…

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 15,941,045AGAINST: 428,537

Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2”): 15,941,045 for, 428,537 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 : The Company's stockholders approved an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Prox…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 5,704,196 for, 100,622 against, 884 abstained.

FOR

FOR: 5,704,196AGAINST: 100,622ABSTAIN: 884

Largest asset managers voting on “To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total nu” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
JANUS INVESTMENT FUND	1,772,021	0	0	For
Vanguard	1,675,430	0	0	For
T. Rowe Price	587,672	0	0	For
BlackRock	390,103	0	0	For
Artisan	251,283	0	0	For
Charles Schwab	123,656	0	0	For
American Century	0	91,230	0	Against
Fidelity	76,653	0	0	For
OLD WESTBURY FUNDS INC	54,469	0	0	For
Lord Abbett	54,435	0	0	For
TIAA	49,103	0	0	For
JANUS ASPEN SERIES	42,402	0	0	For
FINANCIAL INVESTORS TRUST	38,632	0	0	For
Brighthouse	36,133	0	884	For
Pacific Life	36,870	0	0	For
Invesco	35,339	0	0	For
State Street	31,124	5	0	For
Equitable	30,800	0	0	For
Delaware/Macquarie	30,140	0	0	For
Principal	28,926	0	0	For
Jackson National	27,935	0	0	For
AIG/SunAmerica	26,143	0	0	For
Simplify Exchange Traded Funds	23,294	0	0	For
Direxion Shares ETF Trust	23,016	0	0	For
Waddell & Reed	22,182	0	0	For

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

5. 3. The compensation of the Company's named executive officers as described in the Proxy Statement

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%

FOR: 15,585,020AGAINST: 781,212

Details: description as filed, official tally, votes by 285 asset managers

Description as filed by funds: Advisory vote to approve executive compensation.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“3. The compensation of the Company's named executive officers as described in the Proxy Statement”): 15,585,020 for, 781,212 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 81 asset managers voting on “Advisory vote to approve executive compensation.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
JANUS INVESTMENT FUND	1,772,021	0	0	For
Vanguard	1,596,441	78,989	0	For
T. Rowe Price	587,672	0	0	For
Artisan	517,473	0	0	For
BlackRock	390,103	0	0	For
Charles Schwab	0	123,656	0	Against
American Century	0	91,230	0	Against
Fidelity	76,349	304	0	For
OLD WESTBURY FUNDS INC	54,469	0	0	For
Lord Abbett	54,435	0	0	For
TIAA	49,103	0	0	For
JANUS ASPEN SERIES	42,402	0	0	For
FINANCIAL INVESTORS TRUST	38,632	0	0	For
Brighthouse	36,133	0	884	For
Pacific Life	36,870	0	0	For
Invesco	35,339	0	0	For
State Street	31,122	7	0	For
Equitable	30,800	0	0	For
Delaware/Macquarie	30,140	0	0	For
Principal	28,926	0	0	For
Jackson National	27,935	0	0	For
AIG/SunAmerica	26,143	0	0	For
Simplify Exchange Traded Funds	23,294	0	0	For
Direxion Shares ETF Trust	23,016	0	0	For
Waddell & Reed	22,182	0	0	For

Fund voting reports, all 81 managers: 5,710,941 for, 361,339 against, 884 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 226 asset managers voting on “Advisory vote to approve executive compensation.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Janus Henderson	2,487,193	0	For
BAKER BROS. ADVISORS LP	1,969,798	0	For
Avoro Capital Advisors LLC	923,102	0	For
T. Rowe Price	741,349	0	For
RTW INVESTMENTS, LP	536,622	0	For
RA CAPITAL MANAGEMENT, L.P.	420,953	0	For
BlackRock	363,890	1,976	For
Rock Springs Capital Management LP	285,931	0	For
State Street	224,130	28	For
Bain Capital Life Sciences Investors, LLC	196,995	0	For
ARMISTICE CAPITAL, LLC	175,883	0	For
TCG Crossover Management, LLC	149,283	0	For
Fidelity	147,109	0	For
Polar Capital Holdings Plc	125,365	0	For
Charles Schwab	0	123,668	Against
ArrowMark Colorado Holdings LLC	0	98,806	Against
American Century	0	94,071	Against
Ensign Peak Advisors, Inc	91,042	0	For
EcoR1 Capital, LLC	75,000	0	For
EMERALD MUTUAL FUND ADVISERS TRUST	66,359	0	For
Northern Trust	63,629	10	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	62,261	0	For
LORD, ABBETT & CO. LLC	61,427	0	For
FRED ALGER MANAGEMENT, LLC	3,918	55,738	Mixed
Nuveen	59,492	0	For

Institutional-manager reports, all 226 managers: 10,216,957 for, 588,684 against, 16 not voted. Showing the 25 largest; see all in the interactive database.

6. 2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%

FOR: 18,444,828AGAINST: 110,517

Details: description as filed, official tally, votes by 80 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 18,444,828 for, 110,517 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 80 asset managers below reported 5,802,154 for, 2,664 against, 884 abstained.

FOR

FOR: 5,802,154AGAINST: 2,664ABSTAIN: 884

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
JANUS INVESTMENT FUND	1,772,021	0	0	For
Vanguard	1,675,430	0	0	For
T. Rowe Price	587,672	0	0	For
BlackRock	390,103	0	0	For
Artisan	251,283	0	0	For
Charles Schwab	123,656	0	0	For
American Century	91,230	0	0	For
Fidelity	76,653	0	0	For
OLD WESTBURY FUNDS INC	54,469	0	0	For
Lord Abbett	54,435	0	0	For
TIAA	49,103	0	0	For
JANUS ASPEN SERIES	42,402	0	0	For
FINANCIAL INVESTORS TRUST	38,632	0	0	For
Brighthouse	36,133	0	884	For
Pacific Life	36,870	0	0	For
Invesco	35,339	0	0	For
State Street	31,124	5	0	For
Equitable	30,800	0	0	For
Delaware/Macquarie	30,140	0	0	For
Principal	28,926	0	0	For
Jackson National	27,935	0	0	For
AIG/SunAmerica	26,143	0	0	For
Simplify Exchange Traded Funds	23,294	0	0	For
Direxion Shares ETF Trust	23,016	0	0	For
Waddell & Reed	22,182	0	0	For

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

Largest MADRIGAL PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,875,427 shares outstanding at the time of that meeting.

Fund voting reports: top MADRIGAL PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	JANUS INVESTMENT FUND	8.92%
2	Vanguard	8.43%
3	T. Rowe Price	2.96%
4	Artisan	2.60%
5	BlackRock	1.96%
6	Charles Schwab	0.62%
7	American Century	0.46%
8	Fidelity	0.39%
9	OLD WESTBURY FUNDS INC	0.27%
10	Lord Abbett	0.27%

Institutional-manager reports: top MADRIGAL PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve executive compensation.”, 2023-2024
#	Asset manager	% of shares outstanding
1	Janus Henderson	12.51%
2	BAKER BROS. ADVISORS LP	9.91%
3	Avoro Capital Advisors LLC	4.64%
4	T. Rowe Price	3.73%
5	RTW INVESTMENTS, LP	2.70%
6	RA CAPITAL MANAGEMENT, L.P.	2.12%
7	BlackRock	1.84%
8	Rock Springs Capital Management LP	1.44%
9	State Street	1.13%
10	Bain Capital Life Sciences Investors, LLC	0.99%

Reported MADRIGAL PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

MADRIGAL PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Entities Affiliated with Janus Henderson Group plc	14.60%	DEF14A
Entities Affiliated with Avoro Capital Advisors LLC	10.79%	DEF14A
Entities Affiliated with Baker Bros. Advisors LP	10.79%	DEF14A
Julian Baker	10.79%	DEF14A
Paul A. Friedman, M.D.	10.35%	DEF14A
Rebecca Taub, M.D.	10.35%	DEF14A
Vanguard Group	9.12%	13F
Entities Affiliated with The Vanguard Group	7.92%	DEF14A
BlackRock	7.85%	13F
Entities Affiliated with BlackRock, Inc.	6.10%	DEF14A

Percentages above are of 19,875,427 shares outstanding, as reported by MADRIGAL PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MADRIGAL PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At MADRIGAL PHARMACEUTICALS INC.'s shareholder meeting held June 25, 2024, in the 2023-2024 proxy season, 285 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,840 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve executive compensation. — MADRIGAL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MADRIGAL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2024.

MADRIGAL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.